Zelira Therapeutics Limited
ZLDAF
$0.2992
$0.041616.15%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -3.20M | -13.53M | -23.90M | -23.87M | -23.85M |
| Total Depreciation and Amortization | 232.50K | 273.70K | 313.90K | 328.00K | 344.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.66M | 8.93M | 19.57M | 19.46M | 19.33M |
| Change in Net Operating Assets | 1.14M | 1.14M | 1.14M | 857.40K | 583.30K |
| Cash from Operations | -3.49M | -3.19M | -2.88M | -3.22M | -3.59M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 605.40K | 605.40K | 605.40K | 930.10K | 1.27M |
| Cash from Investing | 605.40K | 605.40K | 605.40K | 930.10K | 1.27M |
| Total Debt Issued | 4.36M | 4.14M | 3.92M | 2.79M | 1.66M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 885.00K | 1.77M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.87M | 2.73M | 2.57M | 2.42M | 2.28M |
| Foreign Exchange rate Adjustments | -10.80K | -10.50K | -10.00K | -6.70K | -3.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -18.90K | 133.10K | 290.10K | 122.40K | -44.80K |